Showing results (771-780 of 6,667) with videos related to

Sort By:
Pageof 667
Annals of Hematology|May 25, 2017
Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO)A García-Noblejas, J Cannata-Ortiz, E Conde, et al.
Annals of Hematology|May 28, 2017
Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institutionYuhua Huang, Huilan Rao, Shumei Yan, et al.
Annals of Hematology|June 1, 1992
A simple elimination of clonogenic tumor cells from human bone marrow in vitro by heat: its application to autologous bone marrow transplantation for B-cell lymphomaY Moriyama, T Goto, S Hashimoto, et al.
Annals of Hematology|June 1, 1992
Frequency and DNA sequence of tal-1 rearrangement in children with T-cell acute lymphoblastic leukemiaA Borkhardt, R Repp, J Harbott, et al.
Annals of Hematology|April 29, 2017
Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicinRebeca Rodríguez-Veiga, Begoña Igual, Pau Montesinos, et al.
Annals of Hematology|May 1, 2017
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trialLukas Weiss, Thomas Melchardt, Alexander Egle, et al.
Annals of Hematology|May 1, 2017
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE studyAlessandro Maria Vannucchi, Srdan Verstovsek, Paola Guglielmelli, et al.
Annals of Hematology|May 28, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialMartin Griesshammer, Guray Saydam, Francesca Palandri, et al.
Annals of Hematology|May 23, 2018
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patientsMarius Bill, Juliane Grimm, Madlen Jentzsch, et al.
Annals of Hematology|April 21, 2018
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practiceMassimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, et al.
Pageof 667